HopeStage
Back to all studies
Recruitment unclearEUCTR 2018-002740-82

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 wee...

This historical record does not confirm current site availability.

Historical research recordUnited KingdomSchizophrenia
The study in practice

Understand this study

What is this study about?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations
United Kingdom
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This is historical registry information. What is the current study status and protocol?

Study clarity

Things to check before joining

Study start dateNot clearly listed
Recruitment status
Recruitment unclear
Enrollment listed in the registry
200
Sponsor
Boehringer Ingelheim Limited
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 2Usually explores whether the intervention may work, while continuing to monitor safety.
Locations
United Kingdom
Age range
Not clearly listed
Official registry ID
EUCTR 2018-002740-82
Official title
Show the full official title

A phase II randomized, double-blinded, placebo-controlled parallel group trial to examine the efficacy and safety of BI 425809 once daily with adjunctive Computerized Cognitive Training over 12 wee...

Recruitment & locations

Status unknown

United Kingdom

Registry details
Historical country statuses

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Boehringer Ingelheim Limited.

Want to explore more studies?

Explore studies